Latest Content

If validated prospectively, the classifier could provide oncologists with clearer prognostic insight, enabling more personalized chemotherapy decisions, earlier intervention for high-risk patients, and potential adaptation across STS and other cancer types.

A chemotherapy-free, MRD-guided regimen achieved deep, durable remissions in untreated MCL with manageable toxicity and the potential for time-limited therapy.

A small set of pre-apheresis biological factors can reliably predict whether patients with DLBCL will achieve the T cell collection efficiency needed for successful CAR T manufacturing

A review of 560 FDA-approved drugs found the FDAAA did not change overall time to first postmarket safety action, but some actions occurred earlier.

Common and rare genetic variants linked to idiopathic pulmonary fibrosis (IPF) and reveals substantial genetic overlap with severe COVID-19, highlighting shared biological pathways and potential therapeutic targets.

Research at the San Antonio Breast Cancer Conference highlights T-DXd's superior efficacy and safety in HER2+ metastatic breast cancer, especially among diverse populations.

Clinicians and health system leaders met in Cleveland, Ohio, on October 23, 2025, to share improvements to value-based care in diabetes and chronic kidney disease.

As value-based care mandates expand, a new survey highlights documentation burdens and burnout risks.

The RAISE program provides awareness and shares comprehensive solutions to address the multifaceted reasons for missing and incomplete data across the real-world data continuum.